Targeting cancer with Click Chemistry

Less than 2% of administered drugs make it to their desired location in the body. Imagine a world where cancer drugs are activated only where they are needed.
Let's do better 

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry inside human patients.
Here's how

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.
Antigen-targeted activator
Binds to the tumor
Protodrugs
Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.
A new approach

Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This  unprecedented flexibility can lead to greater activity and lower toxicity than has been previously possible.

CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.
Our science

Latest news

Press Release
Aug 2, 2023
press
Shasqi Appoints Oncology Luminaries to its Inaugural Scientific Advisory Board, Alongside the Expansion of its Leadership Team
Nature Biotech
Jul 5, 2023
media
'Clicked' drugs: researchers prove the remarkable chemistry in humans
Press Release
Jun 28, 2023
press
Shasqi Publishes Data on Systemic Antigen Targeting Approach Using Click Chemistry to Activate MMAE in Tumors

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?
Join our team
Interested in exploring a collaboration?
Partner with us
Company
About UsLeadershipOur SciencePartnering
Connect
NewsCareersContact
Policies
Privacy PolicyFCOI Policy